Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.54 |
| ▸ | PDXK | O00764 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.54 |
| ▸ | STK16 | O75716 | 1/20 | 0.54 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.54 |
| ▸ | LATS1 | O95835 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12067539 | 0.83 | DHFR (0.56) | PIK3CGPIK3CDPIK3C2BPDXKGAK | |
| SCHEMBL12198179 | 0.82 | PIK3CG (0.78) | PIK3CGPIK3CDPIK3C2BPDXKGAK | |
| SCHEMBL12068931 | 0.80 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3C2BPDXKGAK | |
| SCHEMBL17089216 | 0.80 | PIK3CG (0.55) | PIK3CGPIK3CDABL1EGFRPIK3CA | |
| SCHEMBL10456550 | 0.80 | PIK3CG (0.87) | PIK3CGPIK3CDPIK3C2BPDXKGAK | |
| SCHEMBL14983452 | 0.79 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3C2BPDXKGAK | |
| SCHEMBL7774476 | 0.78 | ADORA2A (0.58) | PIK3CGCLK1ADORA2AADORA1ADORA2B | |
| SCHEMBL7777554 | 0.78 | ADORA2A (0.58) | PIK3CGADORA2AADORA1ADORA2BMAPT | |
| SCHEMBL7777497 | 0.78 | ADORA2A (0.58) | PIK3CGADORA2AADORA1ADORA2BMAPT | |
| SCHEMBL12954844 | 0.78 | PIK3CG (0.70) | PIK3CGPIK3CDPIK3C2BPDXKGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-9139592-B2 | Modulators of Nrf2 and uses thereof | TRT PHARMA INC. (CA) | 2015-09-22 | — | — | US | disclosed |
| US-9139592-B2 | Modulators of Nrf2 and uses thereof | TRT PHARMA INC. (CA) | 2015-09-22 | — | — | US | disclosed |
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2013-05-30 | — | — | US | disclosed |
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | KEAP1, TXNRD1, NFE2L2 | PIK3CG 3893/4885PIK3CD 4031/4885PIK3C2B 3340/4885 |
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | KEAP1, TXNRD1, NFE2L2 | PIK3CG 3893/4885PIK3CD 4031/4885PIK3C2B 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.